Hypha Labs

Hypha Labs

Hypha Labs reincorporated in Nevada during 2024, rebranding from its prior identity as DigiPath, a name associated with consumer testing and home-grow products. Michael Littman took the helm as CEO, steering the firm toward biosynthetic production of tryptamines and other molecules for the clinical psychedelics industry. The transition effectively abandoned a consumer hardware play in favor of a pharmaceutical infrastructure bet, one that relies on emerging changes in drug scheduling and FDA trial pathways. The company's stated technical focus is the development of bioreactor-based production systems to manufacture active pharmaceutical ingredients, with an initial emphasis on psilocybin. Unlike traditional extraction or botanical supply models, Hypha Labs pursues precision fermentation and proprietary biosynthetic pathways to generate compounds at scale. The approach targets clinical researchers and future pharmaceutical manufacturers who require consistent, high-purity molecules for trials or eventual commercial distribution. No commercial revenues or significant partnerships have been disclosed as of early 2025. Hypha Labs trades on the OTC markets, listing a modest public float and limited institutional following. The firm has not disclosed its total assets under management or deployment capacity, reflecting its pre-revenue, research-stage posture. The pivot from DigiPath retained the underlying public vehicle, which allows the firm to raise capital through equity markets rather than traditional venture rounds — a structural feature often observed in speculative biotech micro-caps. February 2024: The company announced the official completion of its name change and corporate shift to focus on biosynthetic psilocybin production (per the firm, February 2024). Hypha Labs occupies the peculiar intersection of a pre-revenue biotech startup and a publicly traded OTC company, giving it a capital-raising mechanism unavailable to most private psychedelics ventures. This dual identity introduces a structural differentiator: retail-investor-fueled funding cycles that bypass the clubby venture rounds dominating the clinical psychedelics space. Whether that structure proves an advantage or a dilutive burden depends entirely on Littman's ability to deliver an operational bioreactor prototype.